Fig. 3
Biodistribution of diabody-based anti-TAG72 tc-ADC and the control ADCs vc-ADC (valine-citrulline linker; anti-TAG72) and nb-ADC (non-binding, anti-PSMA; TCO linker). a Blood kinetics of 125I-labelled tc-ADC administered i.v. at 1 and 5 mg kg−1 dose in tumour-free mice (calculated half-lives of 5.95 and 7.17 h, respectively). Immunostaining of b LS174T colon carcinoma and c OVCAR-3 ovarian carcinoma slices showing TAG72 expression (brown staining). d Biodistribution of 125I-labelled tc-ADC and controls vc-ADC and nb-ADC (2 mg kg−1) 48 h post-injection i.v. in mice-bearing subcutaneous LS174T and OVCAR-3 xenografts, respectively; blood level of tc-ADC comparable to vc-ADC and to level in tumour-free mice at 48 h (Fig. 3a), while nb-ADC levels in blood and other tissues are lower due to faster clearance. Data represent the mean percentage injected dose per gram (% ID g−1) with s.d. (n = 4)
